Free Trial
NASDAQ:ALEC

Alector Q1 2025 Earnings Report

Alector logo
$1.51 -0.03 (-1.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.05 (+3.25%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector EPS Results

Actual EPS
N/A
Consensus EPS
-$0.46
Beat/Miss
N/A
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Alector Earnings Headlines

Alector Names Berkley as Interim CFO After Grasso Departs
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Alector Provides Executive Leadership Update
Cantor Fitzgerald Predicts Alector FY2026 Earnings
Alector president sells shares worth $31,974
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC), a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

View Alector Profile

More Earnings Resources from MarketBeat